Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein
Launched by TEXAS A&M UNIVERSITY · Oct 3, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different types of protein—specifically plant-based proteins like soy and pea versus animal-based proteins like whey—affect older adults' ability to build muscle. The researchers want to understand if the amount and type of certain amino acids in these proteins make a difference in how well the body responds to them, especially in people aged 50 to 95 years. The goal is to find the best protein meal composition to help prevent muscle loss, a condition known as sarcopenia, which can affect mobility and overall health.
To participate, you should be between 50 and 95 years old, have been stable in your weight for the last three months, and be able to walk or use a walking aid. You will also need to be willing to lie down for up to six hours during the study. However, if you have certain chronic diseases, are currently using specific medications, or have other health issues that may interfere with the study, you may not be eligible. If you join, you can expect to contribute to important research that could improve nutritional strategies for older adults and help enhance their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 50-95 years old
- • Stable body-weight (±5%) for the past 3 months
- • Ability to walk, sit down, and stand up (independently or with walking assistance device)
- • Willingness to lay supine in bed for up to 6 hours
- • Willingness and ability to comply with the protocol
- Exclusion Criteria:
- • Established diagnosis and active treatment of chronic disease: Insulin dependent diabetes mellitus, active malignancy, heart disease, kidney disease, liver disease, HIV/AIDS, Asthma (moderate to severe), Hep (A,B, or C)
- • History of untreated metabolic disease including hepatic or renal disorder
- • Presence of acute illness or metabolically unstable chronic illness
- • Hysterectomy
- • Active dependence of alcohol or drugs
- • Use of short course of oral corticosteroids within 4 weeks preceding study day
- • Current use of long-term oral corticosteroids
- • Use of protein or amino acids containing nutritional supplements within 5 days of the first study day
- • Presence of fever within the last 3 days
- • Planned elective surgery requiring 2 or more days of hospitalization during the entire study
- • (Possible) pregnancy
- • Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
- • Already enrolled in another clinical trial
- • Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
- • Known allergy to any of the components of the feeding (soy, pea, or whey - dairy)
- • Established daily diet of vegetarian / vegan composition
- • \<23 MoCa score
About Texas A&M University
Texas A&M University, a leading research institution located in College Station, Texas, is dedicated to advancing knowledge and innovation in various fields, including health sciences. As a prominent clinical trial sponsor, Texas A&M University leverages its extensive resources and expertise to conduct rigorous research aimed at improving patient outcomes and addressing critical health challenges. The university fosters collaboration among multidisciplinary teams of researchers, clinicians, and students, ensuring a comprehensive approach to clinical trials that emphasizes ethical standards, scientific integrity, and community impact. Through its commitment to advancing medical research, Texas A&M University plays a vital role in the development of novel therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
College Station, Texas, United States
Patients applied
Trial Officials
Marielle Engelen, PhD
Principal Investigator
Texas A&M University
Nicolaas Deutz, MD, PhD
Principal Investigator
Texas A&M University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported